Genome-wide association study of type 2 diabetes in Africa
- 1.8k Downloads
Genome-wide association studies (GWAS) for type 2 diabetes have uncovered >400 risk loci, primarily in populations of European and Asian ancestry. Here, we aimed to discover additional type 2 diabetes risk loci (including African-specific variants) and fine-map association signals by performing genetic analysis in African populations.
We conducted two type 2 diabetes genome-wide association studies in 4347 Africans from South Africa, Nigeria, Ghana and Kenya and meta-analysed both studies together. Likely causal variants were identified using fine-mapping approaches.
The most significantly associated variants mapped to the widely replicated type 2 diabetes risk locus near TCF7L2 (p = 5.3 × 10−13). Fine-mapping of the TCF7L2 locus suggested one type 2 diabetes association signal shared between Europeans and Africans (indexed by rs7903146) and a distinct African-specific signal (indexed by rs17746147). We also detected one novel signal, rs73284431, near AGMO (p = 5.2 × 10−9, minor allele frequency [MAF] = 0.095; monomorphic in most non-African populations), distinct from previously reported signals in the region. In analyses focused on 100 published type 2 diabetes risk loci, we identified 21 with shared causal variants in African and non-African populations.
These results demonstrate the value of performing GWAS in Africans, provide a resource to larger consortia for further discovery and fine-mapping and indicate that additional large-scale efforts in Africa are warranted to gain further insight in to the genetic architecture of type 2 diabetes.
KeywordsAfrica Established loci Fine-mapping Genome-wide association study Type 2 diabetes
Africa America Diabetes Mellitus
Durban Diabetes Case Control study
Durban Diabetes Study
Genetic risk score
Genome-wide association study
Minor allele frequency
National Institute for Health Research
Variable number tandem repeat
Type 2 diabetes is a major and growing public health problem, with Africa being the region with the fastest growing prevalence [1, 2, 3]. In addition to lifestyle, genetic factors play a major role in susceptibility to type 2 diabetes. To date, type 2 diabetes genome-wide association studies (GWAS) have uncovered over 400 risk signals, primarily in populations of European [4, 5] and Asian [6, 7, 8] ancestry, with more limited efforts in Hispanics/Latinos [9, 10, 11] and African-Americans [12, 13]. Thus far, type 2 diabetes genetic studies in populations from Africa, which are genetically and environmentally diverse, have focused on the replication of established loci .
Here, we conducted a meta-analysis of type 2 diabetes in up to 4347 African participants to identify genetic risk factors associated with type 2 diabetes in Africans, evaluate previously reported loci and utilise the finer-grained linkage disequilibrium (LD) pattern of African populations to fine-map-associated loci.
South African Zulu individuals were type 2 diabetes cases and controls from two studies: the Durban Diabetes Study (DDS) and the Durban Diabetes Case Control study (DCC). DDS was a population-based cross-sectional study of non-pregnant urban black African adults of Zulu descent, aged >18 years, residing in Durban, South Africa [15, 16]. Further details are provided in the electronic supplementary material (ESM) Methods. Additional type 2 diabetes cases from the same ethnic group and locality were obtained from the DCC, which included individuals with type 2 diabetes attending a diabetes clinic. Type 2 diabetes was defined using WHO criteria [15, 16]. The combined type 2 diabetes cases and controls from DDS and DCC were aggregated into a single Zulu study.
The Africa America Diabetes Mellitus (AADM) study comprised individuals from sub-Saharan Africa, enrolled from university medical centres in Nigeria, Ghana and Kenya. A person with type 2 diabetes was identified using ADA criteria or if he or she was receiving treatment for type 2 diabetes. Probable cases of type 1 diabetes were excluded and controls had no evidence of diabetes based on fasting/2 h glucose or symptoms of suggestive diabetes . The characteristics of the Zulu and AADM participants are shown in ESM Table 1.
Genotyping, quality control and imputation
In total, 2707 African individuals of Zulu descent (2003 women and 704 men) were genotyped using the Illumina Multi-Ethnic Genotyping Array (Illumina, Illumina Way, San Diego, CA, USA). Following sample and variant quality control (QC) (ESM Methods), there were 2578 samples with genotype and phenotype information (1602 cases and 976 controls) and 1,434,868 variants (1,395,345 autosomal and 39,523 on the X chromosome).
The AADM samples were genotyped on the Affymetrix Axiom PANAFR SNP array as described previously . After QC (ESM Methods), there were 1031 cases and 738 controls and 2,141,465 variants (2,080,378 autosomal and 61,087 on the X chromosome) in AADM.
All samples were imputed to a merged panel of 1000 Genomes phase 3  and African samples using IMPUTE2  (Zulu) or positional Burrows–Wheeler transform (PBWT)  using the Sanger imputation server (AADM) (ESM Methods). We retained all imputed SNPs with MAF > 0.01 and imputation information score > 0.4 that were also in a newer version of the imputation panel.
In Zulu samples, association with type 2 diabetes was performed for each variant based on the imputation dosage using a linear mixed model that accounts for the presence of related individuals and any population structure implemented in genome-wide efficient mixed-model association (GEMMA) , adjusting for age, sex and BMI. The kinship matrix was estimated from directly genotyped autosomal variants with MAF > 0.01. In AADM, association with type 2 diabetes was performed for each variant based on the imputation dosage using an additive logistic regression model implemented in SNPTEST v2.5.2  (Oxford University, Oxford, UK www.well.ox.ac.uk/~gav/resources/snptest_v2.5.2_linux_x86_64_dynamic.tgz) adjusting for age, sex, BMI and the first three principal components (PCs) to account for population structure. The number of PCs adjusted for in AADM was determined by testing for the number of PCs using the minimum average partial test . The first three PCs were determined to be significant and thus were adjusted for in the association analyses.
Meta-analysis, signal selection and fine-mapping
Meta-analysis of the Zulu and AADM summary statistics for shared variants was performed using a fixed-effects meta-analysis (weighted for effective sample size) in METAL  and we applied double genomic-control correction (ESM Methods). To identify distinct signals of association, we performed approximate conditional analyses using the joint model implemented in genome-wide complex trait analysis (GCTA) [24, 25] and variants with p < 2.5 × 10−8 in the joint model were selected as signals with genome-wide significance . To estimate meta-analysis ORs, we also performed an inverse-variance-weighted meta-analysis using an approximation of the allelic logeOR and variance from the linear model in the Zulu samples , and the logeOR estimates obtained directly from SNPTEST for the AADM samples.
We used FINEMAP  (C. Benner, University of Helsinki, Finland www.christianbenner.com/finemap_v1.1_x86_64.tgz) to identify likely causal variants within 500 kb either side of the most significant variant at the loci TCF7L2 and AGMO in the African meta-analysis and in Europeans  (ESM Methods).
Comparison with established loci
We used ‘direct’ (same lead variant with p < 0.05 and directionally consistent) and ‘local’ (locus-level) detection to explore the extent to which existing GWAS signals (almost all from non-African samples) were detected in the African GWAS (ESM Methods, ESM Table 2). We used two complementary approaches to test for enrichment of signals detected using the ‘direct’ approach: (1) a binomial test taking significance (p < 0.05) and direction of effect into account; and (2) enrichment of directly detected variants, accounting for the properties of the variants in GARFIELD  (ESM Methods). For loci demonstrating ‘direct’ and/or ‘local’ detection between our African data and existing GWAS signals (ESM Table 2), we performed co-localisation analyses implemented in the R package ‘coloc’  using summary statistics from the largest available European type 2 diabetes GWAS at the time of analysis  (default prior for causal variant sharing set to 0.5) (ESM Methods). Using the weighted allele frequencies and sample sizes from the African meta-analysis and previously reported effect sizes, we estimated the power to detect established variants at the significance thresholds p < 0.05 and p < 2.5 × 10−8 using R version 3.3.0  (ESM Table 2).
We also performed genetic risk score (GRS) analyses to harvest association information from multiple variants. GRSs were calculated as the total number of risk alleles in subsets of the 102 variants at established loci from existing GWAS studies of type 2 diabetes (published before May 2018), primarily in populations of European and Asian ancestry (ESM Table 2).
Testing association of INS-variable number tandem repeat with type 2 diabetes
We used the haplotypic information for INS-variable number tandem repeat (VNTR) generated in African-descent individuals by Stead et al (2003)  to impute INS-VNTR lineages in the Zulu and AADM samples and perform a meta-analysis (ESM Methods). Conditional analysis was performed to detect distinct association signals by inclusion of dosages of the lead type 2 diabetes variants as covariates in the regression model.
Ethical approval was obtained for each participating cohort: the Institutional Review Board for each AADM participating institution and the Biomedical Research Ethics Committee of the University of KwaZulu-Natal for DCC (BF078/08) and DDS (BF030/12). DDS also had UK National Research Ethics Service approval (reference: 14/WM/1061). Written informed consent was obtained from all participants and the study was conducted in accordance with the principles of the Declaration of Helsinki.
Type 2 diabetes susceptibility loci with genome-wide significance in combined Zulu and AADM meta-analysis
Weighted mean RAF
Heterogeneity p value
7.9 × 10−7
1.5 × 10−8
5.3 × 10−13
2.1 × 10−8
5.2 × 10−9
The most significant signal for type 2 diabetes association, rs7903146 at TCF7L2 (p = 5.3 × 10−13), has been widely reported in other ethnic groups [9, 13, 33, 34]. The second signal, rs73284431, (p = 5.2 × 10−9, risk allele frequency = 0.093, specific to individuals of African descent) maps to an intron of AGMO, 491 kb upstream of the DGKB transcription start site. The region is already known to harbour two independent GWAS signals for type 2 diabetes  and fasting glucose [35, 36] (denoted by rs10238625 and rs10276674, 132 kb apart and >379 kb from rs73284431), both of them distinct from our lead variant based on exact conditional analyses (ESM Table 4).
Despite not reaching genome-wide significance, the association with rs12277475 (p = 2.0 × 10−7, ESM Table 3) near the INS (insulin) gene was of interest given previous reports of a significant African-American type 2 diabetes association signal at rs3842770 , 28 kb away. The two lead variants are not in LD (r2 ~ 0.03) in 2959 African samples from the merged imputation reference panel , and reciprocal exact conditional analyses confirmed our signal was not being driven by the reported African-American association signal (ESM Table 5). In our data, rs3842770 showed a more modest association with type 2 diabetes (p = 0.0020 in the joint meta-analysis) than rs12277475. The rs12277475 association was also not driven by the previously reported East Asian type 2 diabetes signal (rs7107784) in this region  (ESM Table 5).
In type 1 diabetes, robust associations with variants at INS-IGF2 have been localised to the INS-VNTR mini-satellite within the INS gene promoter [38, 39]; in Europeans, an association between VNTR class III alleles and type 2 diabetes predisposition has been reported in historical candidate gene studies [40, 41]. To explore the relationship between the rs12277475 signal and VNTR variation, we imputed INS-VNTR genotypes using flanking SNP haplotypes (see Methods and ESM Methods). Of the nine distinct lineages with MAF > 0.01 detected in both Zulu and AADM, the strongest associations were observed for lineage W (p = 0.0001, OR 1.24, ESM Table 6) and lineage K (p = 0.0057, OR 0.85, ESM Table 6). Type 2 diabetes association results for lineages W and K and lead variant rs12277475 were largely unchanged in reciprocal conditional analyses (ESM Tables 7 and 8 [Zulu and AADM, respectively]). We conclude that rs12277475 is likely to represent a novel type 2 diabetes association in this region, independent of previous genome-wide significant associations detected in the close vicinity, and is not acting through the VNTR.
Fine-mapping of TCF7L2 and AGMO
Fine-mapping of TCF7L2 and AGMO identified the most significant variants from the meta-analysis, rs7903146 and rs73284431, as the most likely causal variants with posterior probabilities of association of 0.996 and 0.828, respectively (ESM Table 9). These were the only SNPs in the top configuration of causal variants from FINEMAP (ESM Figs. 1 and 2). At TCF7L2, a second plausible causal variant, rs17746147 (r2 = 0.009 with rs7903146 estimated from the African samples in the merged panel), with posterior probability of association of 0.295, was contained in the second most likely configuration of causal variants (ESM Table 9, ESM Fig. 1). The 99% credible intervals and corresponding results in Europeans are presented in ESM Table 9. Fine-mapping results were comparable when using the stepwise approximate Bayes factor approach  (data not shown).
Detection of established loci
We explored the extent to which previously reported type 2 diabetes association signals could be detected in African-descent individuals. Based on the previously reported effect sizes and the effect allele frequency and sample size from our African meta-analysis, we had sufficient power (80%) to detect three signals (TCF7L2, DNER and SRR) at genome-wide significance (p < 2.5 × 10−8) (ESM Table 2). Only the TCF7L2 variant reached genome-wide significance in our study, whereas both variants in DNER (rs1861612) and SRR (rs391300), originally discovered in Pima Indians and East Asians, respectively, had p > 0.1 (ESM Table 2).
So far, five African-American type 2 diabetes-associated signals have been reported, three of which (two in KCNQ1 and one in HMGA2) were first reported in Europeans and two (INS-IGF2 and HLA-B) were first reported in African-Americans (ESM Table 2) . In our meta-analysis, we detected only a nominal association for the African-American INS-IGF2 signal (rs3842770, p = 0.0020, ESM Table 2). However, we identified another signal at this locus (rs12277475, p = 2.0 × 10−7, ESM Table 3) that is independent of the African-American signal (rs3842770), and this signal co-localises with association in Europeans (posterior probability H4 = 1, ESM Table 10).
In ‘direct’ analyses (same lead variant with p < 0.05 and directionally consistent in the African meta-analysis), we detected 12 of 100 lead variants (ESM Table 2) at established type 2 diabetes loci first reported in non-African ancestry individuals, significantly more than expected by chance (binomial test of enrichment p = 8.14 × 10−6, GARFIELD enrichment OR [95% CI] 3.07 (1.50, 6.28), p = 0.002) (ESM Methods). In addition, detection of ‘local’ signals (at least one variant within the 200 kb region flanking the previously reported index variant [100 kb either side] reaching nominal significance [p < 0.05] after correcting for the effective number of independent tests) identified 11 type 2 diabetes loci, two of them overlapping signals also detected with the direct approach (ESM Table 2). Genetic co-localisation analyses suggested that African and non-African populations share the same causal variants at all 21 loci showing direct or local detection in our data (posterior probability H4 > 0.8, ESM Table 10).
In a meta-analysis of type 2 diabetes from two African populations, we replicated the widely reported association at TCF7L2 (rs7903146) and identified a novel association signal at AGMO (rs73284431) that is distinct from previously reported signals in the region.
Using direct and local detection, we showed the transferability of 21 established type 2 diabetes signals discovered in non-African ancestry populations to Africans and that causal variants at those loci were shared across ancestries. For example, the lead SNP at TCF7L2, rs7903146, shared between African and European ancestries, has been refined as the causal variant by examining LD blocks of West African, Danish, Icelandic and American-African populations [43, 44]. Although the mechanisms through which TCF7L2 variation increases type 2 diabetes risk are largely unknown, recent evidence implicates altered incretin signalling .
We also found evidence for ancestry-specific signals, such as the second intergenic association signal at TCF7L2 that is distinct between European and African populations (indexed by rs17746147). In addition, although not reaching genome-wide significance, we detected an association at the INS-IGF2 locus (rs12277475) that appears to be distinct from the previously reported signals in African-Americans and East Asians in the region. We found no evidence of association between the lead variant and VNTR variation in our study, suggesting that the association at INS-IGF2 in our data is not acting through the VNTR.
In summary, our findings highlight the importance of diverse ancestries for uncovering novel biology. Larger African meta-analyses are warranted to gain further insight on the genetic architecture of type 2 diabetes.
This research has been conducted using the UK Biobank Resource (Application Number 9161).
JC, MeS, AA, FP, IB, MIM, AM, EW, CNR and AAM wrote the manuscript. JC, MeS, AA, TC, GC, APM, IB, MIM, AM and EW contributed to the analysis of the data. AA, FP, CP, APD, GC, AAM, EHY, MaS and CNR contributed to the acquisition of data. AAM, APD and CNR contributed to the phenotyping. FP, IB, MIM, CNR and AAM are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors revised the manuscript critically for important intellectual content and approved the final version to be published.
MIM is a Wellcome Senior Investigator and a National Institute for Health Research (NIHR) Senior Investigator. MIM acknowledges support for this work from Wellcome (090532, 203141, 106130, 098381, 090367), MRC (G0601261) and NIH (U01DK105535, R01DK098032, U01DK085545). The DCC was funded by Servier South Africa, the South African Sugar Association and the Victor Daitz Foundation. CNR, AA, GC and APD are supported by the Intramural Research Program of the National Institutes of Health in the Center for Research on Genomics and Global Health (CRGGH). The CRGGH is supported by the National Human Genome Research Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Center for Information Technology and the Office of the Director at the National Institutes of Health (1ZIAHG200362). IB acknowledges funding from Wellcome (WT206194). The study sponsors were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.
Duality of interest
TC owns shares in Novo Nordisk, Roche and Teva Pharmaceutical Industries. IB and spouse own stock in GlaxoSmithKline and Incyte Corporation. MIM serves on advisory panels for Pfizer, Novo Nordisk and Zoe Global; has received honoraria from Pfizer, Novo Nordisk and Lilly; has stock options in Zoe Global; and has received research funding from AbbVie, AstraZeneca, Boehringer Ingelheim, Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier and Takeda. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
- 2.International Diabetes Federation (2015) Diabetes Atlas (7th Edition). Available from: http://www.diabetesatlas.org
- 15.Hird TR, Pirie FJ, Esterhuizen TM et al (2016) Burden of diabetes and first evidence for the utility of HbA1c for diagnosis and detection of diabetes in urban black South Africans: The Durban Diabetes Study. PLoS One 11(8):e0161966. https://doi.org/10.1371/journal.pone.0161966 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from www.R-project.org/ (accessed 11 May 2016)
- 45.Srinivasan S, Kaur V, Chamarthi B et al (2018) TCF7L2 genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care 41(3):554–561. https://doi.org/10.2337/dc17-1386 CrossRefPubMedPubMedCentralGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.